rs5174 — LRP8 LRP8 R952Q

LRP8 R952Q — A Lipoprotein Receptor Variant in Premature Heart Attack Families

Your heart's arteries are constantly cleared of lipoprotein debris by a network of cell-surface receptors. One of these, LRP8 (also called ApoER2)¹¹ LRP8 (also called ApoER2)
LDL receptor-related protein 8, a member of the LDLR superfamily that binds and internalizes ApoE-containing lipoproteins, does double duty: it clears atherogenic particles from the bloodstream and mediates a protective signaling cascade in platelets. The R952Q missense variant disrupts the cytoplasmic tail of this receptor in a way that amplifies inflammatory signaling and blunts platelet regulation — a combination that has been found repeatedly in families with unusually early heart attacks.

The Mechanism

LRP8 is encoded on the minus strand of chromosome 1 (p32.3). The R952Q substitution — a G→A change in the coding sequence (c.2855G>A), reported as C→T on the genomic plus strand — replaces a positively charged arginine with a neutral glutamine in the intracellular domain of the receptor protein. This region contains signaling docking sites; the amino acid swap alters downstream signal transduction without abolishing receptor expression or ligand binding.

Two distinct mechanisms have been described. First, Shen et al. showed²² Shen et al. showed
Shen GQ et al., Am J Hum Genet 2007 that the Q allele increases activation of [p38 MAPK | p38 mitogen-activated protein kinase, a stress-response kinase that promotes inflammatory gene expression including cytokines and matrix metalloproteinases] when vascular cells are exposed to oxidized LDL. Heightened p38 MAPK activity in arterial wall macrophages and smooth muscle cells accelerates plaque formation and destabilization. Second, LRP8 is expressed on the platelet surface where it mediates ApoE3's inhibitory effect on platelet activation. In mice lacking LRP8, platelet aggregation is dysregulated³³ platelet aggregation is dysregulated
Robertson et al., Thromb Res 2009 — ADP and thrombin trigger excessive aggregation, and in-vivo thrombosis time is prolonged 68–200% depending on allele dose, suggesting a paradoxical platelet hyperreactivity under physiological conditions in humans with impaired LRP8 signaling.

The Evidence

The strongest evidence for R952Q as a cardiovascular risk variant comes from studies specifically enriched for familial and premature disease. In the original discovery cohort of 381 patients with premature CAD/MI versus 560 controls, Shen et al. 2007⁴⁴ Shen et al. 2007 found significant association replicated independently in Italian familial MI cases (248 vs 308 controls) and in the pedigree-based GeneQuest II cohort (441 individuals, 22 families). The association was notably absent in a sporadic, non-familial CAD population, consistent with a variant of moderate penetrance that matters most in a familial context.

A larger haplotype analysis identified a five-SNP risk haplotype TACGC⁵⁵ identified a five-SNP risk haplotype TACGC
Shen et al., Circ Cardiovasc Genet 2014 — containing R952Q as one of its five constituent variants — that was present exclusively in CAD/MI patients and absent in controls across the GeneQuest cohort (P=7.4×10⁻⁷ for CAD; P=2.2×10⁻⁹ for MI), with independent replication in Italian and South Korean cohorts. TACGC homozygotes developed disease earlier and had significantly higher LDL cholesterol than heterozygotes (P<0.05).

The MI risk is further amplified when R952Q co-occurs with the APOE ε4 allele. In 681 Italian subjects (394 MI cases, 287 controls), Martinelli et al. 2009⁶⁶ Martinelli et al. 2009 found that the R952Q QQ/ε4 combination carried an OR of 3.88 (95% CI 1.08–13.9) for MI, more than either variant alone, mediated by progressively lower plasma ApoE concentrations (RR: 0.045, RQ: 0.044, QQ: 0.040 g/L; P=0.047 for trend).

Not all replication attempts succeeded. A large German study including WTCCC data (>6,000 subjects across four European cohorts) found no association⁷⁷ found no association
Lieb et al., J Mol Med 2008. The discrepancy is most plausibly explained by population composition: the positive studies specifically recruited familial early-onset cases, while the negative study included predominantly sporadic disease. R952Q appears to be a moderate-penetrance variant whose effect is most visible in family-enriched cohorts where other shared genetic and environmental risk factors amplify its contribution.

Practical Actions

For T-allele carriers, the most actionable findings center on LDL particle quality (smaller, denser LDL particles are more atherogenic), triglycerides, and thrombotic risk. Monitoring these specific lipid fractions — rather than relying solely on standard total cholesterol — provides the most genotype-relevant picture of cardiovascular risk. The platelet biology findings support particular attention to omega-3 fatty acids, which both reduce platelet reactivity through independent mechanisms and lower triglycerides, addressing two of the pathways disrupted by this variant.

Interactions

The strongest documented interaction is with APOE ε4 (rs429358/rs7412). Carriers of both R952Q (rs5174 TT) and APOE ε4 show the lowest plasma ApoE concentrations and the highest MI odds (OR 3.88), because ApoE is both the ligand cleared by LRP8 and the lipid transport protein whose plasma level is genetically modulated by APOE isoform. When LRP8 receptor function is impaired AND ApoE production or clearance is altered by APOE genotype, the combined dysfunction in lipoprotein clearance is additive.

The TACGC haplotype context (rs7546246, rs2297660, rs3737983, R952Q/rs5174, rs5177) also shows that R952Q does not act entirely alone — it is one node in a multi-SNP haplotype, and the haplotype background partially determines the penetrance of the individual Q allele.